MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from equity
offering
$150,000K
Proceeds from exercise of
stock options under...
$670K
Proceeds from atm
offering, net of...
$11K
Proceeds from exercise of
pre-funded warrant
$3K
Net cash provided by
financing activities
$139,595K
Canceled cashflow
$11,089K
Net decrease in
cash, cash...
$15,911K
Canceled cashflow
$123,684K
Payments of issuance
costs related to...
$9,477K
Principal payments on term
loan
$1,305K
Principal payments on
finance leases
$307K
Maturities of investments
$19,500K
Stock-based compensation
$2,509K
Prepaid expenses and
other current assets
-$697K
Non-cash lease costs
$388K
Other assets
-$306K
Depreciation and
amortization
$150K
Accretion of term loan
discount and issuance...
$68K
Net cash (used in)
provided by investing...
-$105,036K
Net cash used in
operating activities
-$18,648K
Canceled cashflow
$19,500K
Canceled cashflow
$4,118K
Interest income
$1,182K
Other income
(expense), net
$188K
Purchase of investments
$124,486K
Net loss
-$17,927K
Accrued expenses and
other current...
-$3,012K
Purchase of property and
equipment
$50K
Canceled cashflow
$1,370K
Accounts payable
-$1,210K
Other non-current
liabilities
-$418K
Net accretion of
discounts on investments
$199K
Loss from operations
-$18,966K
Interest expense
$331K
Preclinical Costs
-$65K
Research and development
expenses
$13,606K
General and
administrative expenses
$5,360K
Canceled cashflow
$65K
Clinical And Development
Costs
$8,280K
Personnel And Related
Costs
$3,175K
Stockbased Compensation
Expense
$1,201K
Other Research Costs
$1,015K
Back
Back
Cash Flow
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)
source: myfinsight.com